Medical Diagnostic Laboratory with a Bacteriology Laboratory, St. Louis Regional Children's Hospital, 31-503 Kraków, Poland.
Department of Medical Diagnostics, Faculty of Pharmacy, Jagiellonian University Medical College, 30-688 Kraków, Poland.
Biomolecules. 2021 Nov 2;11(11):1623. doi: 10.3390/biom11111623.
Cluster of differentiation 93 (CD93), also known as complement component 1q receptor 1 is a transmembrane glycoprotein expressed in endothelial and hematopoietic cells and associated with phagocytosis, cell adhesion, angiogenesis and inflammation. The extracellular part, soluble CD93 (sCD93), is released to body fluids in inflammation. Data on sCD93 in kidney diseases are limited. Our aim was to evaluate serum sCD93 in long-term kidney transplant recipients as a marker of inflammation and endothelial dysfunction that may be potentially useful in early recognition of graft dysfunction. Seventy-eight adult patients with functioning kidney graft and stable clinical state were examined at least one year after kidney transplantation. Serum sCD93 was measured by enzyme immunosorbent assay. Estimated glomerular filtration rate (eGFR) and albuminuria or proteinuria were assessed at baseline and over one-year follow-up. Increased sCD93 was associated with lower baseline eGFR independently of the confounders. Moreover, sCD93 was negatively associated with eGFR during one-year follow-up in simple analysis; however, this was not confirmed after adjustment for confounders. Baseline sCD93 was positively associated with baseline albuminuria and with increased proteinuria during the follow-up. Serum sCD93 was not correlated with other studied inflammatory markers (interleukin 6, C-reactive protein, procalcitonin and C3 and C4 complement components). To the best of our knowledge, this is the first report regarding the concentrations of sCD93 in kidney transplant recipients and one of the first reports showing the inverse association between sCD93 and renal function. Serum sCD93 should be further evaluated as a diagnostic and prognostic marker in renal transplantation.
分化簇 93（CD93），也称为补体成分 1q 受体 1，是一种跨膜糖蛋白，在血管内皮细胞和造血细胞中表达，并与吞噬作用、细胞黏附、血管生成和炎症有关。可溶性 CD93（sCD93）的细胞外部分被释放到炎症中的体液中。关于肾脏疾病中 sCD93 的数据有限。我们的目的是评估长期肾移植受者血清 sCD93 作为炎症和内皮功能障碍的标志物，这可能有助于早期识别移植物功能障碍。检查了至少在肾移植后 1 年处于稳定临床状态的 78 例成人肾功能正常的患者。通过酶联免疫吸附试验测定血清 sCD93。在基线和 1 年随访时评估估计肾小球滤过率（eGFR）和白蛋白尿或蛋白尿。在调整了混杂因素后，发现 sCD93 与较低的基线 eGFR 独立相关。此外，sCD93 在简单分析中与 1 年随访期间的 eGFR 呈负相关；然而，在调整了混杂因素后，这一点没有得到证实。基线 sCD93 与基线白蛋白尿和随访期间蛋白尿增加呈正相关。血清 sCD93 与其他研究的炎症标志物（白细胞介素 6、C 反应蛋白、降钙素原和 C3 和 C4 补体成分）无相关性。据我们所知，这是第一项关于肾移植受者 sCD93 浓度的报告，也是第一项显示 sCD93 与肾功能呈负相关的报告之一。应进一步评估血清 sCD93 作为肾移植的诊断和预后标志物。
